CTOR news

3 The company announced a 120% increase in LYMPHIR unit sales for Q4 2026 fueled by expanded commercial reach. The preliminary data indicates strong institutional demand and successful coverage expansion for the CTCL treatment.

Citius Oncology reported a 120% increase in wholesale units sold in the fourth quarter, citing expanded commercial coverage and continued institutional demand for its oncology drug LYMPHIR.

Citus reported a 78% quarter-over-quarter increase in new institutions ordering LYMPHIR and raised revenue recognition via wholesale orders, signaling a strong commercial launch despite delayed revenue impact.

Citius Oncology reported significant commercial momentum for its cancer drug LYMPHIR, with new institutional orders rising 78% due to expanding formulary approval. This growth reflects in increased wholesale demand, positioning the company to accelerate top-line revenue through the remainder of the …

Citius Oncology presented Phase 1 data at ASCO showing LYMPHIR combined with pembrolizumab achieved 24% overall response rate and 48% clinical benefit rate in heavily pre-treated gynecologic cancer patients, including 33% response rate in endometrial cancer. The encouraging efficacy and tolerability…

Citius Oncology highlighted Phase 1 data for LYMPHIR combined with pembrolizumab showing 24% overall response rate and 20.5 months median progression-free survival in heavily pre-treated patients with recurrent or refractory gynecologic malignancies. The positive clinical signals in checkpoint inhib…